ClinicalTrials.gg
RecruitingNCT07533942Updated Oct 29, 2026

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

A Phase 2 interventional study of JZP3507 in Meningioma, sponsored by Jazz Pharmaceuticals. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 29, 2026Site recruiting status changed3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.

Planned enrollment
52nd of 107
30 · median 30
Started
2026
with 4 others
Phase 2
46 of 129
10 open now
Primary completion
2028-10
later than 25 of 37 live
Registered
129th of 129
by date

Among the 129 studies in Meningioma with a site in United States, this one is the 52nd largest by planned enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2026, is one of 46 in phase 2, reaches primary completion later than 25 of the 37 other live ones, and was the 129th registered.

Meningioma

255 studies on the registry are indexed under Meningioma; 85 are open to participants now.

Browse Meningioma studies →

Open to participants now

27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Meningioma with a site in United States, or all of them as a file.
02

Study summary

This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.

03

Conditions studied

  • Meningioma

Browse trials for

Keywords

  • Grade 2 Meningioma
  • Grade 3 Meningioma
  • JZP3507
  • Recurrent Meningioma
  • ONC206
  • H3 K27me3 loss
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Age

  1. Is ≥ 18 years of age at the time of signing the .

    Type of Participant and Disease Characteristics

  2. Has confirmed Grade 2 or 3 meningioma.
  3. Has failed, is not a candidate for, or has declined standard of care treatment for meningioma. Note: There is no limit on the number of prior systemic therapies.
  4. Has , as assessed by the investigator. Measurable disease is defined as at least one lesion measuring ≥ 10 mm on perpendicular dimensions by contrast-enhanced MRI performed within 28 days prior to study enrollment.
  5. Has progressive disease (PD) per Response Assessment in Neuro-Oncology (RANO) criteria, as assessed by the investigator using axial, contrast-enhanced T1-weighted magnetic resonance imaging (MRI). PD is defined as an increase in size of the measurable primary lesion on imaging by at least 15% in sum of product of target lesions since last treatment or between scans separated by no more than 6 months. The presence of a new lesion would also qualify as PD.
  6. Is able to submit historic disease-related imaging from at least 9 months prior to study entry to central imaging vendor (preferably all available disease-related imaging from initial diagnosis onwards).
  7. Is able to swallow oral tablets.
  8. Has a Performance Status (KPS) of at least 70.
  9. Has laboratory test results meeting the following parameters within 14 days before the start of study intervention:

    1. ≥ 1.0 × 109/L and ≥ 75 × 109/L.
    2. Total ≤ 1.5 × (ULN) (participants with Gilbert's syndrome may be included with total bilirubin > 1.5 × ULN if direct bilirubin is ≤ 1.5 × ULN).
    3. Aspartate () and alanine aminotransferase (ALT) ≤ 2.5 × ULN. Note: For participants with documented baseline liver , the following limits will apply: ≤ 5 × ULN for transaminase.
    4. ≥ 50 mL/min as calculated by the Cockcroft Gault equation (or estimated [eGFR] > 60 mL/min/1.73 m2) or serum creatinine ≤ 1.5 × ULN.
  10. Has an expected survival of at least 12 weeks, as predicted by the physician.
  11. Is able to submit at least 10 (preferably ≥ 15 slides, if available) unstained formalin-fixed paraffin-embedded (FFPE) slides or a tissue block with sufficient material for \~15 slides from participant's tumor tissue to the sponsor.
  12. Has had an MRI within 28 days before the start of study intervention, with the dose stable or decreasing at least 5 days prior to the scan.

    Sex and /Barrier Requirements

  13. Agrees to the following based on sex assigned at birth: is not of or agrees to use appropriate contraception, as defined in protocol, for males and females.

Key Exclusion Criteria:

Medical Conditions

  1. Has known to JZP3507, dordaviprone, or any used in the JZP3507 study intervention formulation.
  2. Has active cardiac disease/condition as defined in the protocol.
  3. Has a known additional that is progressing or has required active treatment within the past 2 years. Exceptions include participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  4. Has an active infection that requires systemic therapy.

    Prior/Concomitant Therapy

  5. Has received any of the following interventions within the specified time periods before the first dose of study intervention or plans to receive any of the following interventions during study participation:

    1. Prior anticancer therapy or agents within 28 days or 5 half-lives, whichever is shorter.
    2. Antibody-based anticancer therapy within 42 days.
    3. Radiotherapy within 24 weeks (\~6 months).
    4. Strong inhibitors within 14 days.
    5. Strong CYP3A4 inducers within 14 days.
    6. Major surgery, open , or significant traumatic injury within 30 days.
  6. Has uncontrolled intercurrent illness or any other medical, psychiatric, or social condition that, in the opinion of the investigator, may interfere with participant safety or the ability to comply with study requirements.

    Prior/Concurrent Clinical Study Experience

  7. Has previous exposure to JZP3507 or dordaviprone from any source.

    Diagnostic Assessments

  8. Has optic nerve sheath meningioma, extracranial meningioma, or meningioma primarily localized spinal cord.
  9. Has more than 3 measurable lesions.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    JZP3507 (ONC206)

    Drug: JZP3507

Interventions

  • Participants will receive oral JZP3507 monotherapy twice daily, on 3 consecutive days per week in 28-day cycles.

    Also known as: ONC206

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria and Evaluated by Blinded Independent Central Review (BICR)

    ORR is the best response of confirmed complete response (CR), partial response (PR), or minor response (MR) during the study, as per RANO criteria

    Time frame: From first dose until death, withdrawal of consent, or lost to follow-up, up to 36 months.

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is the time from the first objective response (CR, PR, or MR) that is subsequently confirmed to documented progressive disease (PD) per RANO criteria or death from any cause.

    Time frame: From first dose until death, withdrawal of consent, or lost to follow-up, up to 36 months.

  2. Time to Response (TTR)

    TTR is the time from the first dose of the study intervention to the first objective response (CR, MR, or PR) subsequently confirmed per RANO criteria.

    Time frame: From first dose until death, withdrawal of consent, or lost to follow-up, up to 36 months.

  3. Disease Control Rate (DCR)

    Proportion of participants who achieved disease control in the study.

    Time frame: From first dose until death, withdrawal of consent, or lost to follow-up, up to 36 months.

  4. Progression-Free Survival (PFS)

    PFS is the time from the first dose of study intervention to the date of first documented PD per RANO criteria (evaluated by BICR) or death from any cause, whichever occurs first.

    Time frame: From first dose to date of documented disease progression or death, up to 36 months.

  5. Overall Survival (OS)

    OS is the time from the first dose of the study intervention to death from any cause.

    Time frame: From first dose until death, or up to 36 months.

  6. Incidence of Grade 3 or higher Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 36 months.

  7. Number of Adverse Events (AEs) Resulting in Study Discontinuation

    Time frame: Up to 36 months.

  8. Maximum Observed Plasma Concentration (Cmax) of JZP3507

    Time frame: Up to 36 months.

  9. Time of Maximum Observed Plasma Concentration (Tmax) of JZP3507

    Time frame: Up to 36 months.

  10. Area Under the Concentration-Time Curve Over a Time interval (AUC(0-τ)) of JZP3507

    Time frame: Up to 36 months.

  11. Terminal Elimination Half-life ( t½) of JZP3507

    Time frame: Up to 36 months.

  12. Apparent Oral Clearance (CL/F)

    Time frame: Up to 36 months.

  13. Apparent Volume of Distribution After Oral Dose (Vz/F)

    Time frame: Up to 36 months.

07

Study locations

6 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy, contact clinicaldatasharing@jazzpharma.com

Data sharing details ↗ · www.jazzpharma.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2028, 27 months after the start.

Of 37 phase 2 interventional studies under Meningioma, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 108. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 16, 2026
StartActual
Jul 16, 2026
Primary completionEst.
Oct 25, 2028
CompletionEst.
Oct 16, 2031
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Sutter Health · San Francisco, United StatesNot yet recruiting→Recruiting
  • Louisiana State University · New Orleans, United StatesNot yet recruiting→Recruiting
Show 3 added (3 United States)
  • Yale-New Haven Hospital - Yale Cancer Center · New Haven, United States
  • Indiana University Health Neurosurgery Clinic · Indianapolis, United States
  • Duke University Medical Center · Durham, United States
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    3 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Sutter Health · San Francisco, United StatesNot yet recruiting→Recruiting
    • Louisiana State University · New Orleans, United StatesNot yet recruiting→Recruiting
    Show 3 added (3 United States)
    • Yale-New Haven Hospital - Yale Cancer Center · New Haven, United States
    • Indiana University Health Neurosurgery Clinic · Indianapolis, United States
    • Duke University Medical Center · Durham, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07533942
Collaborators
Chimerix, Inc.
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Jul 16, 2026
Primary completion
Oct 25, 2028 (estimated)
Completion
Oct 16, 2031 (estimated)
Last update
Oct 29, 2026

Study contacts

Clinical Trial Disclosures & Transparency
Contact
ClinicalTrialDisclosure@jazzpharma.com
215-832-3750

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONC206

Start the discussion